Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Association between baseline tumor size and outcome in patients treated with next-generation immunoncology agents

Date

02 Mar 2020

Session

Poster Display & Cocktail

Presenters

Paolo Tarantino

Citation

Annals of Oncology (2020) 31 (suppl_1): S1-S7. 10.1016/annonc/annonc86

Authors

P. Tarantino1, M. Minotti2, P. Pricolo2, G. Signorelli2, A. Marra1, C. Criscitiello1, M. Locatelli1, C. Belli1, M. Bellomi2, G. Curigliano1

Author affiliations

  • 1 Division Of New Drugs And Early Drug Development, European Institute of Oncology IRCCS, 20141 - Milan/IT
  • 2 Division Of Radiology, European Institute of Oncology IRCCS, 20141 - Milan/IT
More

Resources

Baseline tumor size (BTS) is a known predictor of response to anti-PD(L)1 immune checkpoint inhibitors (ICI) in melanoma and NSCLC patients (pts), with lower BTS predicting better treatment outcome. However, no data are currently available on the role of BTS in other solid tumors as well as for next-generation immuno-oncology agents (NGIO).

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings